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Heart failure is a worldwide health-care problem, recently high-
lighted in a report from the Global Heart Failure Awareness
Programme of the Heart Failure Association of the European
Society of Cardiology.1 For nearly all countries for which there
are data, heart failure consumes 1–2% of expenditure, chiefly
related to the costs of hospitalization. Despite differences in heart
failure aetiology and demographics in high- and middle-income
countries, the need for accurate and speedy diagnosis, access to
life-saving therapies, and appropriate support for individuals and
their families is universal. International guidelines strongly support
disease management programmes,2,3 including follow-up shortly
after discharge from hospital and in the high-risk period (the first
3 months) thereafter. The most recent edition of the American
College of Cardiology/American Heart Association guidelines
suggest that a follow-up visit within 7–14 days and/or a telephone
follow-up within 3 days of hospital discharge are ‘reasonable’, with
a B grading for level of evidence and a IIa class of recommendation.
Standards have also been suggested for disease management
programmes, with the goal of providing a seamless system of care
across primary and hospital care.4 Patient education to support
self-monitoring and self-care, where appropriate, is seen as central
to any such programme.
However, the evidence base for such recommendations is largely
confined to randomized trials from high-income countries. In a
recent meta-analysis of disease management programmes for heart
failure, including 46 studies,5 30 (65%) were based in the USA or
Canada, nine in Europe, six in Australia or New Zealand, and only
one came from a middle-income country (Argentina).
Despite international guidelines, the relevance of a randomized
clinical trial (RCT) to routine practice is often questioned. This
is particularly the case when the RCT is based in a health-care
system that is constructed (and funded) in a very different way
from that found in the geography considering how to organize
heart failure services. Reimbursement authorities and health-care
insurance companies frequently question the relevance of stud-
ies from other geographies. Of course, the biology of the
heart failure is unlikely to be different, but the impact of a
health-care intervention on the pattern of health-care utilization
may be very different. Where the quality or relevance of the
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.. evidence is questioned, partial or no implementation is the likely
scenario.
De Souza and colleagues6 should be congratulated on perform-
ing a high-quality randomized controlled trial of a nurse-based
home intervention, with telephone reinforcement, in the Brazilian
health-care system, where many patients often do not have system-
atic follow-up after discharge from hospital for a variety of reasons,
including cost.
The HELEN II programme consisted of up to four home visits of
an hour’s duration after discharge from hospital. The first occurred
within 10 days of discharge (in keeping with the most recent
North American guidelines), and then at 1 month, 2 months,
and 4 months after discharge. In addition, there were telephone
calls during the programme (four calls of around 10 min) to
reinforce the recommendations made during the home visits, to
check the use of prescribed medication, and to answer questions
about the condition and its treatment. Owing to restrictions
on time and staff, only patients living within 20 km of the two
hospitals involved could be enrolled. The programme did not
enrol patients with heart failure with normal ejection fraction
(HFNEF) or acute coronary syndrome on admission. The primary
outcome was a composite endpoint of time to a first visit to
the emergency department, a hospital readmission, or all-cause
death. An assessment of knowledge of heart-failure and self-care
behaviour was made at baseline and then at 6 months.
Although a small study (252 patients in total), de Souza and
colleagues report a statistically significant reduction in the primary
endpoint, with a relative risk reduction of 27% (1–46%, P= 0.049)
and a number needed to treat (NNT) of only 12 to prevent one
event over 6 months. The cost-effectiveness of this approach will
be reported elsewhere.
Interestingly, the proportion of patients taking a diuretic was
higher at 6 months in the intervention arm (97% vs. 89%), although
the dose was similar to the control arm, suggesting that the effect
of the intervention was to detect or control fluid retention more
strictly. The use of disease-modifying medication was not different,
although the dose of the drugs used is not reported. Knowledge
about heart failure and self-care behaviour was substantially better
in the intervention arm than in the control arm. This is encouraging,
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particularly as the background level of education of the enrolled
patients was low (65% had only elementary school level education).
Although not adding a large number of patients to the evidence
base for nurse-based disease management in heart failure, the
value of this study is in showing that such an approach can work
in a middle-income country, with a health-care system and socioe-
conomic challenges very different from the high-income countries
in which the vast majority of RCTs are conducted. It would be
interesting to see if the effect on health-care utilization persisted
beyond 6 months, and the value for money of the programme.
Heart failure is an increasing problem in most countries: the
HELEN II Study strengthens the evidence that nurse-based inter-
vention after discharge from hospital is beneficial in a wide range
of health-care settings. The only caveat to this is that in systems
where the usual treatment is of high quality the additional value
of ever more contact with a patient is questionable.7 There will
be a ‘sweet’ point where the incremental value of any additional
contact is maximized, both in terms of clinical outcome and in
value for money. In Brazil, regular nurse contact in the 6 months
after discharge from hospital appears to be of considerable value.
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